Article Text

Download PDFPDF
Case report
Elimination of Staphylococcus aureus from the bloodstream using a novel biomimetic sorbent haemoperfusion device
  1. Malin-Theres Seffer1,2,
  2. Gabriele Eden1,
  3. Susanne Engelmann2 and
  4. Jan T Kielstein1
  1. 1Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Lower Saxony, Germany
  2. 2Microbial Proteomics, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany
  1. Correspondence to Professor Jan T Kielstein; kielstein{at}


Removal of bacteria from the blood by means of extracorporeal techniques has been attempted for decades. In late 2019, the European Union licensed the first ever haemoperfusion device for removal of bacteria from the blood. The active ingredient of Seraph 100 Microbind Affinity Blood Filter is ultrahigh molecular weight polyethylene beads with endpoint-attached heparin. Bacteria have been shown to bind to heparin as they would usually do to the heparan sulfate on the cell surface, thereby being removed from the blood stream. We describe the first case of a female chronic haemodialysis patient in which this device was clinically used for a Staphylococcus aureus infection that persisted for 4 days despite antibiotic therapy. After a single treatment, the bacterial load decreased and the blood cultures at the end of a 4 hour haemoperfusion exhibited no bacterial growth.

  • infections
  • drugs: infectious diseases
  • therapeutic indications
  • dialysis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors GE and JTK treated the patient. MTS and SE performed the analysis. All authors contributed to the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests GE and JTK received research funding from ExThera Medical Corporation. JTK recieved speaker fees from ExThera Medical Corportion.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.